Ocuphire Pharma

Ocuphire Pharma is a clinical-stage biopharmaceutical company based in Farmington Hills, Michigan, specializing in the development and commercialization of therapies for various ophthalmic disorders. The company's leading product candidate, Nyxol, is a once-daily, preservative-free eye drop formulation designed to address conditions such as dim light vision disturbances, pharmacologically-induced pupil dilation, and presbyopia. Nyxol is currently undergoing Phase 3 clinical trials and is supported by over a decade of safety and efficacy data from earlier studies. Additionally, Ocuphire is advancing APX3330, an oral tablet aimed at inhibiting pathways associated with retinal diseases like diabetic retinopathy and diabetic macular edema, which is in Phase 2 clinical development. The company also seeks to expand its portfolio through potential acquisitions of other ophthalmic assets and strategic partnerships for global commercialization.